2026-05-31T02:46:30Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/371872026-02-03T10:51:32Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Bravo-Romero, María José author Burgos-Molina, Antonio Manuel author García Aranda, Marilina author Redondo-Bautista, Maximino author Téllez-Santana, Teresa author 2023 Cancer is one of the world’s most significant health problems today. Currently, breast cancer has globally surpassed lung cancer as the most commonly diagnosed cancer in women. In 2020, an estimated 2,261,419 new cases were diagnosed in women worldwide. Therefore, there is a need to understand the processes that can help us better treat this disease. In recent years, research in the fight against cancer has often been based on two treatment modalities. One of them is the use of protein kinase inhibitors, which have been instrumental in the development of new therapeutic strategies. Another crucial route is the use of immunotherapy, which has been touted as a great promise for cancer treatment. Protein kinase alterations can interfere with the effectiveness of other treatments, such as immunotherapy. In this review, we will analyze the role played by protein kinase alterations in breast cancer and their possible impact on the effectiveness of the response to immunotherapy treatments. Bravo, M.J.; Burgos-Molina, A.M.; García-Aranda, M.; Redondo, M.; Téllez, T. Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy. Cancers 2023, 15, 5499. https://doi.org/10.3390/cancers15235499 https://hdl.handle.net/10630/37187 10.3390/cancers15235499 Mamas - Cáncer - Tratamiento Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy